A Phase III Long-Term Study of M610101 in Patients with Atopic Dermatitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220566

Enrollment

200

Registered

2023-01-12

Start date

2023-01-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

M6101:0.75% or 1.5% BID

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with atopic dermatitis over 12 years old Patients with an IGA score of 2 or 3 for atopic dermatitis

Exclusion criteria

Exclusion criteria: Patients complicated with diseases considered inappropriate for participation in clinical trials such as serious cardiac / hepatic / renal / pulmonary / hematologic disease Patients with skin diseases other than atopic dermatitis that affect the evaluation of atopic dermatitis or the safety of the subject

Design outcomes

Primary

Measure	Time frame
Safety after long-term application of M610101 (up to 52 weeks) (adverse events, laboratory tests, vital signs, ECG)	—

Contacts

Public Contact- Clinical Trials Information

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026